← Oncology Approval Tracker

FDA DECISION ·

Sarclisa + pomalidomide + dexamethasone

isatuximab-irfc + pomalidomide + dexamethasone · Sanofi-Aventis U.S.

FDA approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with multiple myeloma after at least two prior therapies, including lenalidomide and a proteasome inhibitor.

LAMPGEN ANALYSIS

Why it matters

Introduced an anti-CD38 antibody option with pomalidomide and dexamethasone.

What research teams should watch

Plan infusion monitoring and notify the blood bank before treatment because compatibility testing can be affected.

PRIMARY RECORDS

Sources